Alexion Pharmaceuticals Inc. is a biopharmaceutical company
focused on serving patients with severe and ultra-rare disorders
through the innovation, development and commercialization of
life-transforming therapeutic products. The company has a market
cap of $20.53 billion; its shares were traded at around $105.00
with a P/E ratio of 59.52 and P/S ratio of 15.89. Alexion
Pharmaceuticals Inc. had an annual average earnings growth of 70.6%
over the past five years.
CEO of Alexion Pharmaceuticals Inc. (
) Leonard Bell sold 140,000 shares on Aug. 16, 2013 at an average
price of $106.08. The total transaction amount was $14,851,200.
Leonard Bell, currently the CEO of Alexion Pharmaceuticals Inc.,
was the primary founder of this company. Before founding Alexion
Pharmaceuticals, Mr. Bell worked at Yale University as an assistant
professor of medicine and pathology and a co-director of the
program in vascular biology.
CEO Leonard Bell also sold 287,989 shares during May, July, and the
beginning of August. CFO and EVP Vikas Sinha also sold 51,847
shares during July and August. Other officers and directors sold
shares as well.
kept his position in ALXN unchanged. He still owns 8,424,567 shares
as of June 30, 2013. On the other hand,
reduced his position in Alexion Pharmaceuticals Inc. by 41.4% and
Alexion Pharmaceuticals Inc. reported its 2013 second quarter
financial results with revenues of $274.7 million and net income of
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in 3
monthly newsletters sent to